Ionic versus nonionic contrast media: safety, tolerance, and rationale for use.
After several years of clinical experience worldwide and numerous high-quality, randomized controlled trials in humans, the marked improvement in patient tolerance and safety of low osmolar contrast media (ionic and nonionic) has been demonstrated. Iohexol (Omnipaque), Iopamidol (Isovue), Ioxaglate (Hexabrix), and Ioversol (Optiray) are all now available in the United States.